Garderet, Laurent;
Gras, Luuk;
Koster, Linda;
Baaij, Laurien;
Hamad, Nada;
Dsouza, Anita;
Estrada-Merly, Noel;
... Niederwieser, Dietger; + view all
(2024)
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).
American Journal of Hematology
, 99
(11)
pp. 2084-2095.
10.1002/ajh.27451.
Preview |
Text
Mc Lornan_American J Hematol - 2024 - Garderet - Global characteristics and outcomes of autologous hematopoietic stem cell.pdf Download (2MB) | Preview |
Abstract
Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 and 2017 from nine national/international registries. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), relapse incidence (RI) and non-relapse mortality (NRM). Median OS amounted to 90.2 months (95% CI 88.2–93.6) and median PFS 36.5 months (95% CI 36.1–37.0). At 24 months, cumulative RI was 33% (95% CI 32.5%–33.4%) and NRM was 2.5% (95% CI 2.3%–2.6%). In the multivariate analysis, superior outcomes were associated with younger age, IgG subtype, complete hematological response at auto-HCT, Karnofsky score of 100%, international staging scoring (ISS) stage 1, HCT-comorbidity index (CI) 0, standard cytogenetic risk, auto-HCT in recent years, and use of lenalidomide maintenance. There were differences in the baseline characteristics and outcomes between registries. While the NRM was 1%–3% at 12 months worldwide, the OS at 36 months was 69%–84%, RI at 12 months was 12%–24% and PFS at 36 months was 43%–63%. The variability in these outcomes is attributable to differences in patient and disease characteristics as well as the use of maintenance and macroeconomic factors. In conclusion, worldwide data indicate that AHCT in MM is a safe and effective therapy with an NRM of 1%–3% with considerable regional differences in OS, PFS, RI, and patient characteristics. Maintenance treatment post-AHCT had a beneficial effect on OS.
| Type: | Article |
|---|---|
| Title: | Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT) |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/ajh.27451 |
| Publisher version: | https://doi.org/10.1002/ajh.27451 |
| Language: | English |
| Additional information: | Copyright © 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10218267 |
Archive Staff Only
 |
View Item |
